Daniel Cressy spent the first 23 years of his life in and out of hospitals — sometimes six to twelve times a year during his worst periods. He had a dream to become a commercial airline pilot, but the FAA would not certify him because of his sickle cell disease. Then he learned something that changed everything: if he could be cured, the FAA would reconsider.
On June 22, 2026, Cressy rang the ceremonial bell at Manning Family Children's Hospital in New Orleans to mark the end of his treatment journey — the first person in Louisiana and the Gulf South to be functionally cured of sickle cell disease using Casgevy, the FDA-approved CRISPR-based gene therapy.
His hemoglobin levels are now the highest they have ever been. He has been free of sickle cell crises. He plans to reapply for his FAA medical certification. And he is calling this next chapter of his life simply "Life 2."
Why This Matters
Sickle cell disease affects approximately 100,000 Americans — and Louisiana has the highest per-capita rate of any state. It is a disease that disproportionately affects Black Americans, causes lifelong chronic pain, organ damage, stroke risk, and shortened life expectancy, and has been chronically underfunded relative to diseases of similar severity.
For decades, the only potential cure was bone marrow transplantation — a treatment that required a matched donor, carried substantial risks of its own, and was accessible to only a small fraction of affected patients.
Casgevy changes that calculus. But access to this therapy remains far from universal, and the Gulf South's first success story reveals as much about the barriers as about the breakthrough.
What We Know So Far
From Manning Family Children's Hospital's official announcement, Verite News, and Healthline's coverage:
- Patient : Daniel Cressy, 23, of Metairie, Louisiana
- Treatment facility : Manning Family Children's Hospital, New Orleans — one of a select group of U.S. centers offering both FDA-approved gene therapies for sickle cell disease
- Therapy : Casgevy (exagamglogene autotemcel) — FDA-approved December 8, 2023; first FDA-approved treatment using CRISPR gene-editing technology
- Process : Stem cells collected from Cressy in late 2025 and sent to Scotland for genetic modification; returned to New Orleans in March 2026; Cressy received chemotherapy to clear diseased cells; modified cells infused March 18, 2026
- Outcome : Functionally cured — hemoglobin levels at their highest ever; no sickle cell crises since treatment
- Cost : The drug alone cost approximately $2.2 million; covered through Louisiana Medicaid after a two-year approval process
- Historical significance : First patient in Louisiana and the Gulf South to achieve this result through CRISPR gene therapy
Where the Treatment Is Available and Who Cannot Access It Yet
Manning Family Children's Hospital is now one of a select few U.S. programs offering both FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia. As of 2026, approximately 100+ patients nationally have been cured through these therapies.
But the barriers to access remain substantial:
Cost: At $2.2 million for the drug alone plus treatment costs, Casgevy is among the most expensive therapies in human history. Cressy's treatment was eventually covered by Louisiana Medicaid, but the approval process took two years — during which he continued living with a disease that was already curable.
Geographic concentration: The specialized centers required to deliver this therapy are concentrated in major academic medical centers. Patients in rural Louisiana, Mississippi, and Alabama — states with some of the highest sickle cell disease burdens — face long travel requirements, time away from work, and logistical barriers that create de facto inequality of access.
Complexity: The treatment process spans more than two years, involves stem cell collection, overseas genetic processing, chemotherapy, and approximately a month of inpatient recovery. Not all patients can or will complete this journey.
What Doctors and Experts Say
"I feel like God chose me to be the first one in the state because my story, once I do finally become a commercial pilot, is going to be inspirational for a lot of people," Cressy said at the June 22 ceremony.
Lucio Fragoso, president and CEO of Manning Family Children's Hospital, described the achievement as "a transformational moment" in the management of a disease that has burdened the Gulf South disproportionately for generations.
Cressy has also launched the Privileged Pilots Project, a nonprofit dedicated to helping aspiring pilots facing health and life challenges and expanding access to opportunities for underserved communities.
What the Evidence Shows — and What It Does Not
Casgevy was approved based on clinical trial data showing that approximately 93.5% of patients achieved freedom from severe vaso-occlusive crises for at least 12 months after treatment. "Functionally cured" is a medical term of precision — it means the disease is no longer driving the crises and complications that defined a patient's daily life. It does not mean the genetic mutation is completely eliminated from every cell, but it does mean the functional hemoglobin production is restored sufficiently to prevent sickling.
Long-term follow-up data are still accumulating. The therapy was only FDA-approved in December 2023, making Cressy's outcome among the earliest real-world reports of durable functional cure outside of clinical trials.
MedicalDaily Evidence Check
- Therapy : Casgevy (exagamglogene autotemcel) — FDA-approved December 8, 2023 for sickle cell disease in patients 12 and older
- Mechanism : CRISPR/Cas9 gene editing of hematopoietic stem cells to increase fetal hemoglobin production
- Clinical trial efficacy : 93.5% of patients free of severe vaso-occlusive crises for 12+ months
- Cressy's outcome : Functionally cured; highest hemoglobin levels ever; no crises since infusion in March 2026
- Key limitation : Long-term durability data are still accumulating; the therapy has been available only since December 2023
- What readers should know : This is a genuine functional cure for the majority of patients — but access remains limited by cost, geographic availability, and treatment complexity
Who Is Most Affected?
Sickle cell disease affects approximately 100,000 Americans and is most prevalent in:
- Black Americans, who account for approximately 90% of U.S. cases
- People of Hispanic, Southern European, Middle Eastern, and South Asian ancestry
- Residents of Louisiana, Mississippi, Alabama, Georgia, and other Deep South states with the highest per-capita incidence rates
- Young adults who have survived childhood complications but face ongoing organ damage, chronic pain, and shortened life expectancy
Casgevy is FDA-approved for patients 12 and older with sickle cell disease who have had recurrent vaso-occlusive crises.
Symptoms and Warning Signs to Watch For
Sickle cell disease produces symptoms across a lifetime. Current patients and families should watch for:
- Severe, sudden pain in the chest, abdomen, bones, or joints (vaso-occlusive crisis requiring emergency care)
- Fever above 101°F — infection is a leading cause of death in sickle cell disease
- Stroke symptoms — sudden weakness, numbness, severe headache, vision loss, or difficulty speaking
- Acute chest syndrome — chest pain, cough, fever, and difficulty breathing
- Signs of severe anemia — extreme pallor, fatigue, rapid heartbeat
Any of these symptoms requires emergency medical evaluation.
What You Can Do Now
- If you or a family member has sickle cell disease , ask your hematologist whether gene therapy is an appropriate option for your specific case.
- Contact Manning Family Children's Hospital (New Orleans) or one of the other centers offering Casgevy to learn about patient eligibility and the treatment process.
- If Medicaid coverage is your primary payer , ask your hematologist for help navigating the prior authorization process — the two-year delay in Cressy's case is an unacceptable norm that can be challenged.
- Connect with the Sickle Cell Disease Association of America at sicklecelldisease.org for current information on treatment access, clinical trials, and advocacy.
- Learn about Cressy's nonprofit, the Privileged Pilots Project , which is expanding its mission to help underserved individuals access health and opportunity resources.
Cost and Access: What Patients Should Know
Casgevy costs approximately $2.2 million for the drug alone, with total treatment costs potentially exceeding $3 million. Coverage varies:
- Medicaid : Louisiana's program covered Cressy's treatment after a two-year approval process. Other state Medicaid programs have variable coverage.
- Commercial insurance : Coverage is product- and plan-specific; prior authorization is required.
- Patient assistance : Vertex Pharmaceuticals, Casgevy's manufacturer, offers patient support services. Contact Vertex at vertexgenetherapy.com for current enrollment information.
What Happens Next
Manning Family Children's Hospital will continue tracking Cressy's outcomes as part of long-term follow-up. Additional patients in Louisiana and the Gulf South are expected to begin the Casgevy evaluation process now that the facility has demonstrated the capability. Cressy plans to reapply for his FAA medical certification in the coming month.
The Bottom Line
Daniel Cressy is free of sickle cell disease — functionally, at the cellular level, because of a CRISPR gene therapy that was approved by the FDA just over two years ago. His case is not just a remarkable personal story; it demonstrates that a disease that has disproportionately burdened Black communities in the Gulf South for generations now has a genuine cure. The barriers to access — cost, geographic concentration, treatment complexity, insurance delay — are not medical problems. They are policy problems, and they are solvable.
